According to a systematic review and meta-analysis of randomized trials, GLP-1 agonists may have little effect on the risk of obesity-related cancers[1][4][6]. One study showed a significant risk reduction for gallbladder cancer by 65%, meningioma by 63%, pancreatic cancer by 59%, and liver cancer by 53% after 15 years of follow-up in patients taking GLP-1RAs instead of insulin[1]. Risks of ovarian, colorectal, multiple myeloma, esophageal, endometrial, and renal cancers were reduced by 48%, 46%, 41%, 40%, 26%, and 24%, respectively[1]. Another analysis of 170,030 adults with diabetes showed a 7% lower risk of obesity-related cancers with GLP-1RAs versus DPP-4 inhibitors, with 16% fewer cases of colon cancer and 28% fewer cases of rectal cancer[2]. A meta-analysis of 50 studies found no significant difference in overall cancer risk (MH-OR 1.05), but in obese patients the risk of uterine cancer was reduced to an MH-OR of 0.24[4]. Conversely, the risk of thyroid cancer increased to MH-OR 1.55 and colorectal cancer to MH-OR 1.27 in some trials[4]. GLP-1RAs are contraindicated in multiple endocrine neoplasia type 2 due to the potential risk of thyroid tumors[1].